Vemurafenib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vemurafenib: From BRAF V600E-Mutant Melanoma to HIV Infection
One-Sentence Summary
Vemurafenib is a BRAF V600E-selective kinase inhibitor, contextually used to treat BRAF V600E-mutant melanoma (the drug’s formal original-indication text is not present in this Evidence Pack, but is consistently implied by the accompanying literature and rationale entries). The TxGNN model’s top-ranked prediction is HIV infectious disease, but this signal is currently supported by 0 clinical trials and 0 publications, and the pack itself flags “no known mechanistic association” between BRAF inhibition and HIV pathways. This is a pure knowledge-graph similarity prediction with no biological or clinical corroboration to date.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this Evidence Pack (no taiwan_regulatory.licenses entries); contextually consistent with BRAF V600E-mutant melanoma based on accompanying literature |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 97.65% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack (flagged as a High-severity data gap). Based on contextual information within the pack — including literature titles referencing “vemurafenib for BRAF-mutated melanoma” and repeated mentions of “BRAF V600E-specific inhibition” — vemurafenib appears to function as a selective inhibitor of the mutated BRAF kinase, a key node in the MAPK signaling pathway that drives proliferation in BRAF V600E-positive tumors.
For this top-ranked prediction, the relationship between the original indication (oncogenic BRAF-driven signaling) and the predicted new indication (HIV infectious disease) has no established mechanistic basis. The Evidence Pack’s own rationale for this candidate states explicitly: “BRAF V600E inhibition has no known association with HIV viral replication or host immune pathways; this is purely a knowledge-graph similarity prediction.”
In other words, this candidate was surfaced by the TxGNN model on the basis of network-embedding similarity rather than any pharmacological, virological, or immunological rationale. It should be treated as a hypothesis-generating signal only, not as evidence of biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Cytotoxicity
Contextual evidence in this Evidence Pack (literature entries repeatedly describing vemurafenib as a melanoma-directed BRAF V600E inhibitor) supports classifying this as an antineoplastic/targeted agent, though no structured DrugBank category or toxicity data were provided.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BRAF V600E kinase inhibitor) — inferred from contextual literature, not from structured category data |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Note: this drug also carries a Blocking-severity data gap in the underlying Evidence Pack — official label warnings/contraindications have not yet been retrieved, which prevents any formal S1 safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (HIV infectious disease) has no clinical trials, no supporting literature, and no plausible mechanistic link per the pack’s own rationale — it is an L5, model-only signal that does not meet the evidentiary bar to advance.
To proceed, the following is needed:
- Official product label / SmPC data (warnings, contraindications, DDI) to close the Blocking-severity safety data gap
- Confirmed mechanism of action (MOA) sourced from DrugBank or equivalent regulatory documentation
- Independent biological rationale (in vitro or in vivo) connecting BRAF/MAPK inhibition to HIV pathophysiology before any experimental investment
- Formal confirmation of the original approved indication and regulatory status, since no EU marketing authorization is currently on file
Additional observation (secondary signal, not part of the primary S0 candidate): Among the other nine ranked predictions in this pack, female breast carcinoma (rank 8) stands out with a materially higher evidence tier (L3, “Research Question” stage) — it has one early-phase (withdrawn) trial and 19 literature citations, including case reports of BRAF V600E-mutant triple-negative breast cancer as well as a conflicting case report of vemurafenib-associated breast cancer progression. If further repurposing exploration is warranted for this molecule, that candidate — not the HIV signal — would be the more defensible starting point, though the mixed direction of effect (efficacy vs. progression) still requires subgroup clarification before advancing.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.